Live feed10:30:00·2dPRReleaseCemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 TrialREGN· Regeneron Pharmaceuticals Inc.Health CareOriginal source
